LENZ Therapeutics, Inc.(LENZ) - 2024 Q1 - Quarterly Results

Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3 CLARITY study to be presented at Key Opinion Leader event planned for June 18, 2024 Completed merger with Graphite Bio and concurrent $53.5 million private placement Cash, cash equivalents and marketable securities ...